


Market Data	
52-week high/low	SAR 96.6/65.6
Market Cap	SAR 15,200 mln
Shares Outstanding	200 mln
Free-float	45.8%
12-month ADTV	503,146
Bloomberg Code	MOUWASAT AB



■ Solid Y/Y Growth in Net Profit

November 03, 2025

Upside to Target Price	10.5%	Rating	Neutral
Expected Dividend Yield	2.6%	Last Price	SAR 76.00
Expected Total Return	13.1%	12-mth target	SAR 84.00

MOUWASAT	3Q2025	3Q2024	Y/Y	2Q2025	Q/Q	RC Estimate
Sales	777	711	9%	796	(2%)	819
Gross Profit	324	318	2%	356	(9%)	360
Gross Margins	42%	45%		45%		44%
Operating Profit	212	168	26%	203	4%	202
Net Profit	200	150	33%	187	7%	181

(All figures are in SAR mln)

- Mouwasat recorded revenues of SAR 777 mln in 3Q25, slightly below our estimate of SAR 819 mln, as we had anticipated stronger demand. Revenues grew +9% Y/Y but declined -2% Q/Q, the Y/Y increase driven by higher numbers of both inpatients and outpatients. On a Q/Q basis, revenues were impacted by the holiday season during 3Q25.
- Gross profit reached SAR 324 mln, up +2% Y/Y but down -9% Q/Q, coming below our expectations. The gross margin contracted sharply by -310 bps Y/Y and -313 bps Q/Q, standing at 42%.
- Operating profit came in line with our estimates at SAR 212 mln, rising +26% Y/Y and +4% Q/Q, mainly supported by a reduction in impairment loss provisions. The operating margin expanded unexpectedly by +370 bps Q/Q and +176 bps Y/Y, reaching 27%. Our expectations had indicated operating margin pressure this quarter; however, we do not anticipate these levels to be sustained in upcoming quarters.
- Net profit exceeded our estimate of SAR 181 mln and the market consensus of SAR 185 mln, coming in at SAR 200 mln – a strong +33% Y/Y and +7% Q/Q increase, The robust performance was driven by revenue growth, lower impairment provisions, and reduced Zakat expenses.
- Mouwasat announced the commencement of trial operations for its new hospital in Yanbu Industrial City during 3Q25, with full commercial operations expected to begin in 4Q25. We believe the ongoing expansions at the Riyadh and Qatif hospitals, along with the construction of new hospitals in Abha and Al Ahsa, will likely exert pressure on margins over the short and long term. We maintain our target price and recommendation.

Raghad Aljumah
raghad.s.aljumah@riyadcapital.com
+966-11-203-6816

■ Stock Rating

Buy	Neutral	Sell	Not Rated
Expected Total Return Greater than +15%	Expected Total Return between -15% and +15%	Expected Total Return less than -15%	Under Review/ Restricted

The expected percentage returns are indicative, stock recommendations also incorporate relevant qualitative factors

For any feedback on our reports, please contact research@riyadcapital.com

Riyad Capital is a Saudi closed joint stock company with paid-up capital of SAR 500 million. Licensed by the Saudi Arabian Capital Market Authority (No. 07070-37). Commercial Registration No. 1010239234. Head Office: 3128 Financial Boulevard, 6671 Al Aqeeq Dist., Riyadh 13519, Kingdom of Saudi Arabia.

The information in this report was compiled in good faith from various public sources believed to be reliable. Whilst all reasonable care has been taken to ensure that the facts stated in this report are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable. Riyad Capital makes no representations or warranties whatsoever as to the accuracy of the data and information provided and, in particular, Riyad Capital does not represent that the information in this report is complete or free from any error. This report is not, and is not to be construed as, an offer to sell or solicitation of an offer to buy any financial securities. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this report. Riyad Capital accepts no liability whatsoever for any loss arising from any use of this report or its contents, and neither Riyad Capital nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof. Riyad Capital or its employees or any of its affiliates or clients may have a financial interest in securities or other assets referred to in this report. Opinions, forecasts or projections contained in this report represent Riyad Capital's current opinions or judgment as at the date of this report only and are therefore subject to change without notice. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections which represent only one possible outcome. Further, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified and future actual results or events could differ materially. The value of, or income from, any investments referred to in this report may fluctuate and/or be affected by changes. Past performance is not necessarily an indicative of future performance. Accordingly, investors may receive back less than originally invested amount. This report provides information of a general nature and does not address the circumstances, objectives, and risk tolerance of any particular investor. Therefore, it is not intended to provide personal investment advice and does not take into account the reader's financial situation or any specific investment objectives or particular needs which the reader may have. Before making an investment decision the reader should seek advice from an independent financial, legal, tax and/or other required advisers due to the investment in such kind of securities may not be suitable for all recipients. This research report might not be reproduced, nor distributed in whole or in part, and all information, opinions, forecasts and projections contained in it are protected by the copyright rules and regulations.